Editas Medicine


Editas Medicine Stock Quote
$19.73 -$0.62 -3.0%
BATS BZX Real Time Price as of October 18, 2019, 4:00 p.m. EDT View Interactive EDIT Charts

Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.

News & Analysis: Editas Medicine

The Fool has written over 100 articles on Editas Medicine.


Market Moves


Editas Medicine Remains on Track

With a new CEO in place and a groundbreaking "in vivo" dosing study approaching, the gene-editing leader is rightly excited for the future.

Is Editas Medicine a Buy?

High risk? Definitely. But this small biotech also has the potential for high returns over the long run.

Interactive Chart